AUGUST NEWSFEED

  • Immunotherapy Treatment Shown Safe in Type 1 Diabetes Clinical Trial
    A small clinical trial showed an immune system therapy was safe for people with type 1 diabetes, British researchers report. The immunotherapy also showed signs of helping to keep insulin production steady in people newly diagnosed with the disease, the study authors said. Read the full article here: CBS NEWS
  • FDA Clears Novo Nordisk’s Diabetes Drug to Reduce Cardiovascular Risk
    U.S. Food and Drug Administration (FDA) has approved an expanded use of Novo’s diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke. This is the first time the FDA has cleared a diabetes drug for reducing risks of heart attack, stroke and cardiovascular deaths in patients with type 2 diabetes. Read the full story here: Reuters.
  • Metformin Still Cost-effective for Diabetes Prevention
    Metformin plus vitamin B12 supplementation saves between $7 and $42 per patient per year relative to placebo when the drug plus supplementation strategy is used to prevent progression from prediabetes to diabetes, an updated cost analysis of the Diabetes Prevention Program (DPP) and the Diabetes Prevention Program Outcomes Study (DPPOS) suggests. Read the full article here: Medscape
  • Online Game Helps Diabetics Control Blood Sugar
    A new study shows patients saw lasting improvement while playing team-based diabetes education game. The study included 456 U.S. Veterans Affairs diabetes patients with poor blood sugar control while on oral medications. Half played a specially designed, team-based online diabetes education game for six months. The others were assigned to a control group that played a civics education game. The results showed that playing an online game can help those with diabetes get better control of their blood sugar. Read full story here: WebMD.
Disclaimer. The content, information, and links on this page are intended for informational and educational purposes only, and does NOT constitute any medical professional advice.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.